Takeaway

• In patients with heavily pre-treated HR+/HER2- advanced breast cancer with disease progression following endocrine-based therapy, sacituzumab govitecan improved progression-free survival (PFS) by 34% compared with standard chemotherapy.
• No new safety signals emerged.
• The antibody-drug conjugate sacituzumab govitecan should be considered a potential treatment option for these patients.

Why this...